{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:47:19Z","timestamp":1789026439112,"version":"build-2803163510"},"reference-count":115,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human telomeres are tandem arrays that are predominantly composed of 5\u2032-TTAGGG-3\u2032 nucleotide sequences at the terminal ends of chromosomes. These sequences serve 2 primary functions: they preserve genomic integrity by protecting the ends of chromosomes, preventing inappropriate degradation by DNA repair mechanisms, and they prevent loss of genetic information during cellular division. When telomeres shorten to reach a critical length, termed the Hayflick limit, cell senescence or death is triggered. Telomerase is a key enzyme involved in synthesizing and maintaining the length of telomeres within rapidly dividing cells and is upregulated across nearly all malignant cells. Accordingly, targeting telomerase to inhibit uncontrolled cell growth has been an area of great interest for decades. In this review, we summarize telomere and telomerase biology because it relates to both physiologic and malignant cells. We discuss the development of telomere- and telomerase-targeted therapeutic candidates within the realm of myeloid malignancies. We overview all mechanisms of targeting telomerase that are currently in development, with a particular focus on imetelstat, an oligonucleotide with direct telomerase inhibitory properties that has advanced the furthest in clinical development and has demonstrated promising data in multiple myeloid malignancies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009903","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T16:34:06Z","timestamp":1684773246000},"page":"4302-4314","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Telomerase-targeted therapies in myeloid malignancies"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6167-4322","authenticated-orcid":false,"given":"Julian A.","family":"Waksal","sequence":"first","affiliation":[{"name":"1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9580-1446","authenticated-orcid":false,"given":"Claudia","family":"Bruedigam","sequence":"additional","affiliation":[{"name":"2QIMR Berghofer Medical Research Institute, Brisbane, Australia"},{"name":"3School of Biomedical Sciences, The University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[{"name":"4Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8057-6613","authenticated-orcid":false,"given":"Catriona H. M.","family":"Jamieson","sequence":"additional","affiliation":[{"name":"5UC San Diego Moores Cancer Center and Sanford Stem Cell Clinical Center, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John O.","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"issue":"18","key":"2023082115442273800_bib1","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1073\/pnas.86.18.7049","article-title":"Conservation of the human telomere sequence (TTAGGG)n among vertebrates","volume":"86","author":"Meyne","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2023082115442273800_bib2","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1073\/pnas.85.18.6622","article-title":"A\u00a0highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes","volume":"85","author":"Moyzis","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6274","key":"2023082115442273800_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/345458a0","article-title":"Telomeres shorten during ageing of human fibroblasts","volume":"345","author":"Harley","year":"1990","journal-title":"Nature"},{"issue":"4","key":"2023082115442273800_bib4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/0022-2836(92)90096-3","article-title":"Telomere end-replication problem and cell aging","volume":"225","author":"Levy","year":"1992","journal-title":"J\u00a0Mol Biol"},{"issue":"4","key":"2023082115442273800_bib5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1006\/jmbi.1997.1305","article-title":"Possible mechanisms for the regulation of telomere length","volume":"273","author":"Kowald","year":"1997","journal-title":"J\u00a0Mol Biol"},{"issue":"18","key":"2023082115442273800_bib6","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1101\/gad.1346005","article-title":"Shelterin: the protein complex that shapes and safeguards human telomeres","volume":"19","author":"de Lange","year":"2005","journal-title":"Genes Dev"},{"issue":"2","key":"2023082115442273800_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/ng1097-231","article-title":"Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2","volume":"17","author":"Broccoli","year":"1997","journal-title":"Nat Genet"},{"issue":"5","key":"2023082115442273800_bib8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1083\/jcb.200703020","article-title":"Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA","volume":"179","author":"Stagno D'Alcontres","year":"2007","journal-title":"J\u00a0Cell Biol"},{"issue":"6618","key":"2023082115442273800_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/385740a0","article-title":"Control of telomere length by the human telomeric protein TRF1","volume":"385","author":"van Steensel","year":"1997","journal-title":"Nature"},{"issue":"1","key":"2023082115442273800_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cell.2009.06.021","article-title":"Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication","volume":"138","author":"Sfeir","year":"2009","journal-title":"Cell"},{"issue":"7157","key":"2023082115442273800_bib11","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/nature06065","article-title":"Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1","volume":"448","author":"Denchi","year":"2007","journal-title":"Nature"},{"issue":"6585","key":"2023082115442273800_bib12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1126\/science.abn6840","article-title":"Structural basis of human telomerase recruitment by TPP1-POT1","volume":"375","author":"Sekne","year":"2022","journal-title":"Science"},{"issue":"31","key":"2023082115442273800_bib13","doi-asserted-by":"crossref","first-page":"e2201662119","DOI":"10.1073\/pnas.2201662119","article-title":"Shelterin is a dimeric complex with extensive structural heterogeneity","volume":"119","author":"Zinder","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2023082115442273800_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molcel.2013.06.006","article-title":"The telomere deprotection response is functionally distinct from the genomic DNA damage response","volume":"51","author":"Cesare","year":"2013","journal-title":"Mol Cell"},{"issue":"5406","key":"2023082115442273800_bib15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.283.5406.1321","article-title":"p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2","volume":"283","author":"Karlseder","year":"1999","journal-title":"Science"},{"issue":"1","key":"2023082115442273800_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/ncb2388","article-title":"Puma and p21 represent cooperating checkpoints limiting self-renewal and chromosomal instability of somatic stem cells in response to telomere dysfunction","volume":"14","author":"Sperka","year":"2011","journal-title":"Nat Cell Biol"},{"issue":"9","key":"2023082115442273800_bib17","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1073\/pnas.0836098100","article-title":"Telomere attrition and Chk2 activation in human heart failure","volume":"100","author":"Oh","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2023082115442273800_bib18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/acel.12476","article-title":"Dysfunctional telomeres induce p53-dependent and independent apoptosis to compromise cellular proliferation and inhibit tumor formation","volume":"15","author":"Wang","year":"2016","journal-title":"Aging Cell"},{"issue":"5","key":"2023082115442273800_bib19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/0092-8674(89)90610-7","article-title":"Monovalent cation-induced structure of telomeric DNA: the G-quartet model","volume":"59","author":"Williamson","year":"1989","journal-title":"Cell"},{"issue":"19","key":"2023082115442273800_bib20","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1093\/nar\/gkl655","article-title":"Sequence, topology and structure","volume":"34","author":"Burge","year":"2006","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2023082115442273800_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nchem.1548","article-title":"Quantitative visualization of DNA G-quadruplex structures in human cells","volume":"5","author":"Biffi","year":"2013","journal-title":"Nat Chem"},{"issue":"18","key":"2023082115442273800_bib22","doi-asserted-by":"crossref","first-page":"11593","DOI":"10.1073\/pnas.182256799","article-title":"Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription","volume":"99","author":"Siddiqui-Jain","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2023082115442273800_bib23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nchembio864","article-title":"An RNA G-quadruplex in the 5' UTR of the NRAS proto-oncogene modulates translation","volume":"3","author":"Kumari","year":"2007","journal-title":"Nat Chem Biol"},{"key":"2023082115442273800_bib24","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1038\/ncomms8643","article-title":"Telomeric G-quadruplexes are a substrate and site of localization for human telomerase","volume":"6","author":"Moye","year":"2015","journal-title":"Nat Commun"},{"issue":"4942","key":"2023082115442273800_bib25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1126\/science.1689074","article-title":"Functional evidence for an RNA template in telomerase","volume":"247","author":"Shippen-Lentz","year":"1990","journal-title":"Science"},{"issue":"7859","key":"2023082115442273800_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41586-021-03415-4","article-title":"Structure of human telomerase holoenzyme with bound telomeric DNA","volume":"593","author":"Ghanim","year":"2021","journal-title":"Nature"},{"issue":"5328","key":"2023082115442273800_bib27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1126\/science.277.5328.955","article-title":"Telomerase catalytic subunit homologs from fission yeast and human","volume":"277","author":"Nakamura","year":"1997","journal-title":"Science"},{"issue":"5228","key":"2023082115442273800_bib28","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.7544491","article-title":"The RNA component of human telomerase","volume":"269","author":"Feng","year":"1995","journal-title":"Science"},{"issue":"8","key":"2023082115442273800_bib29","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3390\/genes12081188","article-title":"Mechanism of human telomerase reverse transcriptase","volume":"12","author":"Yik","year":"2021","journal-title":"Genes"},{"issue":"5193","key":"2023082115442273800_bib30","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1126\/science.7605428","article-title":"Specific association of human telomerase activity with immortal cells and cancer","volume":"266","author":"Kim","year":"1994","journal-title":"Science"},{"issue":"3","key":"2023082115442273800_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng.3781","article-title":"Systematic analysis of telomere length and somatic alterations in 31 cancer types","volume":"49","author":"Barthel","year":"2017","journal-title":"Nat Genet"},{"issue":"16","key":"2023082115442273800_bib32","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/sj.onc.1207518","article-title":"Hallmarks of senescence in carcinogenesis and cancer therapy","volume":"23","author":"Shay","year":"2004","journal-title":"Oncogene"},{"issue":"3","key":"2023082115442273800_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1074-7613(00)80316-7","article-title":"Telomerase activity in hematopoietic cells is associated with self-renewal potential","volume":"5","author":"Morrison","year":"1996","journal-title":"Immunity"},{"issue":"2","key":"2023082115442273800_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1520-6408(1996)18:2<173::AID-DVG10>3.0.CO;2-3","article-title":"Telomerase activity in human germline and embryonic tissues and cells","volume":"18","author":"Wright","year":"1996","journal-title":"Dev Genet"},{"issue":"11","key":"2023082115442273800_bib35","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm1197-1271","article-title":"Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines","volume":"3","author":"Bryan","year":"1997","journal-title":"Nat Med"},{"issue":"5","key":"2023082115442273800_bib36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrg2763","article-title":"Alternative lengthening of telomeres: models, mechanisms and implications","volume":"11","author":"Cesare","year":"2010","journal-title":"Nat Rev Genet"},{"issue":"13","key":"2023082115442273800_bib37","first-page":"3557","article-title":"Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes","volume":"54","author":"Ohyashiki","year":"1994","journal-title":"Cancer Res"},{"issue":"5","key":"2023082115442273800_bib38","first-page":"1155","article-title":"Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes","volume":"5","author":"Ohyashiki","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2023082115442273800_bib39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/leu.2008.319","article-title":"Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms","volume":"23","author":"Bernard","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2023082115442273800_bib40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.leukres.2010.07.042","article-title":"Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms","volume":"35","author":"Spanoudakis","year":"2011","journal-title":"Leuk Res"},{"issue":"8","key":"2023082115442273800_bib41","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/leu.2013.57","article-title":"Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia","volume":"27","author":"Aalbers","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2023082115442273800_bib42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.exphem.2013.03.007","article-title":"Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy","volume":"41","author":"Ruella","year":"2013","journal-title":"Exp Hematol"},{"issue":"4","key":"2023082115442273800_bib43","first-page":"619","article-title":"Clinical implications of telomerase activity levels in acute leukemia","volume":"3","author":"Ohyashiki","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023082115442273800_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00277-007-0395-2","article-title":"Correlation of telomerase activity to apoptosis and survival in adult acute lymphoblastic leukemia: an Egyptian single-center study","volume":"87","author":"Asfour","year":"2008","journal-title":"Ann Hematol"},{"issue":"2","key":"2023082115442273800_bib45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1751-553X.2009.01178.x","article-title":"Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival","volume":"32","author":"Wang","year":"2010","journal-title":"Int J Lab Hematol"},{"key":"2023082115442273800_bib46","doi-asserted-by":"crossref","first-page":"763930","DOI":"10.3389\/fcvm.2021.763930","article-title":"Senescence-associated secretory phenotype as a hinge between cardiovascular diseases and cancer","volume":"8","author":"Banerjee","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2023082115442273800_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-2395-3-1","article-title":"Telomeres, oxidative stress and inflammatory factors: partners in cellular senescence?","volume":"3","author":"Correia-Melo","year":"2014","journal-title":"Longev Healthspan"},{"issue":"12","key":"2023082115442273800_bib48","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/ncb2621","article-title":"Telomerase directly regulates NF-\u03baB-dependent transcription","volume":"14","author":"Ghosh","year":"2012","journal-title":"Nat Cell Biol"},{"issue":"10","key":"2023082115442273800_bib49","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/13495","article-title":"Inhibition of telomerase limits the growth of human cancer cells","volume":"5","author":"Hahn","year":"1999","journal-title":"Nat Med"},{"issue":"3","key":"2023082115442273800_bib50","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood-2002-07-2015","article-title":"Telomerase levels control the lifespan of human T lymphocytes","volume":"102","author":"Roth","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2023082115442273800_bib51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nsmb.2530","article-title":"Structure of active dimeric human telomerase","volume":"20","author":"Sauerwald","year":"2013","journal-title":"Nat Struct Mol Biol"},{"issue":"10","key":"2023082115442273800_bib52","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.str.2015.08.006","article-title":"Structural basis of telomerase inhibition by the highly specific BIBR1532","volume":"23","author":"Bryan","year":"2015","journal-title":"Structure"},{"issue":"24","key":"2023082115442273800_bib53","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1093\/emboj\/20.24.6958","article-title":"A\u00a0highly selective telomerase inhibitor limiting human cancer cell proliferation","volume":"20","author":"Damm","year":"2001","journal-title":"EMBO J"},{"issue":"4","key":"2023082115442273800_bib54","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2003-12-4322","article-title":"Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532","volume":"105","author":"El-Daly","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2023082115442273800_bib55","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1002\/jcb.27301","article-title":"Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies","volume":"119","author":"Biray Avci","year":"2018","journal-title":"J\u00a0Cell Biochem"},{"issue":"3","key":"2023082115442273800_bib56","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/10428194.2012.704034","article-title":"Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells","volume":"54","author":"Bashash","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2023082115442273800_bib57","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.cdd.4401670","article-title":"Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function","volume":"12","author":"Del Bufalo","year":"2005","journal-title":"Cell Death Differ"},{"key":"2023082115442273800_bib58","doi-asserted-by":"crossref","first-page":"120402","DOI":"10.1016\/j.lfs.2022.120402","article-title":"Telomerase inhibition on acute myeloid leukemia stem cell induced apoptosis with both intrinsic and extrinsic pathways","volume":"295","author":"Rafat","year":"2022","journal-title":"Life Sci"},{"issue":"1","key":"2023082115442273800_bib59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/2159-8290.CD-14-0609","article-title":"Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine","volume":"5","author":"Mender","year":"2015","journal-title":"Cancer Discov"},{"issue":"3","key":"2023082115442273800_bib60","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ccell.2020.05.020","article-title":"Telomere stress potentiates STING-dependent anti-tumor immunity","volume":"38","author":"Mender","year":"2020","journal-title":"Cancer Cell"},{"issue":"8","key":"2023082115442273800_bib61","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/ijms20081823","article-title":"Telomerase-targeted cancer immunotherapy","volume":"20","author":"Mizukoshi","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2023082115442273800_bib62","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00262-017-1994-y","article-title":"Phase I\/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer","volume":"66","author":"Lilleby","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"2023082115442273800_bib63","doi-asserted-by":"crossref","first-page":"572172","DOI":"10.3389\/fimmu.2020.572172","article-title":"Long-term outcomes of a phase i study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer","volume":"11","author":"Brunsvig","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"2023082115442273800_bib64","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1007\/s00262-021-03024-0","article-title":"Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial","volume":"70","author":"Filaci","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2023082115442273800_bib65","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.1365-2141.1999.01620.x","article-title":"Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage","volume":"106","author":"Trentin","year":"1999","journal-title":"Br J Haematol"},{"issue":"16","key":"2023082115442273800_bib66","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/cncr.30696","article-title":"Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia","volume":"123","author":"Khoury","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"2023082115442273800_bib67","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.4049\/jimmunol.174.6.3798","article-title":"Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer","volume":"174","author":"Su","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"33","key":"2023082115442273800_bib68","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1038\/sj.onc.1208760","article-title":"Lipid modification of GRN163, an N3'--&gt;P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition","volume":"24","author":"Herbert","year":"2005","journal-title":"Oncogene"},{"issue":"22","key":"2023082115442273800_bib69","doi-asserted-by":"crossref","first-page":"9494","DOI":"10.1158\/0008-5472.CAN-10-0233","article-title":"The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines","volume":"70","author":"Joseph","year":"2010","journal-title":"Cancer Res"},{"issue":"7","key":"2023082115442273800_bib70","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/leu.2008.81","article-title":"Telomerase inhibitor GRN163L inhibits myeloma cell growth in\u00a0vitro and in\u00a0vivo","volume":"22","author":"Shammas","year":"2008","journal-title":"Leukemia"},{"issue":"18","key":"2023082115442273800_bib71","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2018022012","article-title":"Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells","volume":"2","author":"Wang","year":"2018","journal-title":"Blood Adv"},{"issue":"23","key":"2023082115442273800_bib72","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1158\/1078-0432.CCR-13-1117","article-title":"A\u00a0phase I trial of imetelstat in children with refractory or recurrent solid tumors: a children's oncology group phase I Consortium Study (ADVL1112)","volume":"19","author":"Thompson","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2023082115442273800_bib73","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/annonc\/mdu550","article-title":"A\u00a0randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer","volume":"26","author":"Chiappori","year":"2015","journal-title":"Ann Oncol"},{"issue":"22","key":"2023082115442273800_bib74","doi-asserted-by":"crossref","first-page":"3065-3065","DOI":"10.1182\/blood.V128.22.3065.3065","article-title":"Telomerase inhibition with imetelstat eradicates \u03b2-catenin activated blast crisis chronic myeloid leukemia stem cells","volume":"128","author":"Ma","year":"2016","journal-title":"Blood"},{"key":"2023082115442273800_bib75","first-page":"2860","article-title":"Telomerase inhibition impairs self-renewal of \u00df-catenin activated myeloproliferative neoplasm progenitors","volume":"130","author":"Ma","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2023082115442273800_bib76","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am J Hematol"},{"issue":"12","key":"2023082115442273800_bib77","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1080\/10428194.2017.1312371","article-title":"Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery","volume":"58","author":"Chuzi","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2023082115442273800_bib78","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood.V118.21.3843.3843","article-title":"a potent telomerase inhibitor, inhibits the spontaneous growth of CFU-Meg in vitro from essential thrombocythemia patients but not from healthy individuals","volume":"118","author":"Brunold","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2023082115442273800_bib79","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/leu.2017.78","article-title":"Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis","volume":"31","author":"Mosoyan","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2023082115442273800_bib80","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023082115442273800_bib81","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.3324\/haematol.2020.252817","article-title":"Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat","volume":"106","author":"Oppliger Leibundgut","year":"2021","journal-title":"Haematologica"},{"key":"2023082115442273800_bib82","unstructured":"Geron announces removal of full clinical hold on imetelstat IND. Accessed 3 November 2014. https:\/\/ir.geron.com\/investors\/press-releases\/press-release-details\/2014\/Geron-Announces-Removal-of-Full-Clinical-Hold-on-Imetelstat-IND\/default.aspx."},{"issue":"10","key":"2023082115442273800_bib83","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A\u00a0pilot study of the telomerase inhibitor imetelstat for myelofibrosis.","volume":"373","author":"Tefferi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7053","key":"2023082115442273800_bib84","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/nature03836","article-title":"Conditional telomerase induction causes proliferation of hair follicle stem cells","volume":"436","author":"Sarin","year":"2005","journal-title":"Nature"},{"issue":"7251","key":"2023082115442273800_bib85","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature08137","article-title":"Telomerase modulates Wnt signalling by association with target gene chromatin","volume":"460","author":"Park","year":"2009","journal-title":"Nature"},{"issue":"7261","key":"2023082115442273800_bib86","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature08283","article-title":"An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA","volume":"461","author":"Maida","year":"2009","journal-title":"Nature"},{"key":"2023082115442273800_bib87","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1038\/ncomms5599","article-title":"Telomerase stimulates ribosomal DNA transcription under hyperproliferative conditions","volume":"5","author":"Gonzalez","year":"2014","journal-title":"Nat Commun"},{"issue":"23","key":"2023082115442273800_bib88","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1073\/pnas.0503095102","article-title":"The telomerase reverse transcriptase regulates chromatin state and DNA damage responses","volume":"102","author":"Masutomi","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2023082115442273800_bib89","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.3390\/ijms21186550","article-title":"Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors","volume":"21","author":"Baerlocher","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2023082115442273800_bib90","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/nat.2020.0918","article-title":"Characterization of in\u00a0vitro G-quadruplex formation of imetelstat telomerase inhibitor","volume":"31","author":"Carloni","year":"2021","journal-title":"Nucleic Acid Ther"},{"key":"2023082115442273800_bib91","doi-asserted-by":"publisher","DOI":"10.1101\/2023.04.25.538357","article-title":"Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as therapeutic strategy for acute myeloid leukemia","volume":"28","author":"Bruedigam","year":"2023","journal-title":"bioRxiv. Preprint posted"},{"issue":"26","key":"2023082115442273800_bib92","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"2023082115442273800_bib93","volume-title":"Presented at American Society of Hematology National Conference","author":"Mascarenhas","year":"2020"},{"issue":"9","key":"2023082115442273800_bib94","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2023082115442273800_bib95","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"2023082115442273800_bib96","first-page":"721","article-title":"Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis","volume":"23","author":"Mascarenhas","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"suppl 1","key":"2023082115442273800_bib97","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-138823","article-title":"Imetelstat treatment results in clinical benefits, including improved overall survival, in patients with higher-risk triple-negative myelofibrosis relapsed\/refractory to janus kinase inhibitors (JAKi)","volume":"136","author":"Kiladjian","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2023082115442273800_bib98","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00277-021-04683-w","article-title":"Favorable overall survival with imetelstat in relapsed\/refractory myelofibrosis patients compared with real-world data","volume":"101","author":"Kuykendall","year":"2022","journal-title":"Ann Hematol"},{"issue":"10","key":"2023082115442273800_bib99","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMe1508740","article-title":"Treating myeloproliferation\u2013on target or off?","volume":"373","author":"Armanios","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023082115442273800_bib100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/90609","article-title":"Toll-like receptors: critical proteins linking innate and acquired immunity","volume":"2","author":"Akira","year":"2001","journal-title":"Nat Immunol"},{"issue":"22","key":"2023082115442273800_bib101","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2217\/fon-2022-0235","article-title":"Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design","volume":"18","author":"Mascarenhas","year":"2022","journal-title":"Future Oncol"},{"issue":"14","key":"2023082115442273800_bib102","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023082115442273800_bib103","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood.V85.9.2315.bloodjournal8592315","article-title":"Telomerase activity in normal leukocytes and in hematologic malignancies","volume":"85","author":"Counter","year":"1995","journal-title":"Blood"},{"issue":"11","key":"2023082115442273800_bib104","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.leukres.2015.09.003","article-title":"Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide","volume":"39","author":"Beier","year":"2015","journal-title":"Leuk Res"},{"issue":"3","key":"2023082115442273800_bib105","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1038\/bcj.2016.13","article-title":"Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis","volume":"6","author":"Tefferi","year":"2016","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023082115442273800_bib106","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023082115442273800_bib107","first-page":"2598-2598","article-title":"On-target activity of imetelstat correlates with clinical benefits, including overall survival (OS), in heavily transfused non-del(5q) lower risk MDS (LR-MDS) relapsed\/refractory (R\/R) to erythropoiesis stimulating agents (ESAs)","volume":"138","author":"Santini","year":"2021","journal-title":"Blood"},{"key":"2023082115442273800_bib108","author":"Phase III","year":"2023"},{"issue":"22","key":"2023082115442273800_bib109","doi-asserted-by":"crossref","first-page":"578-578","DOI":"10.1182\/blood.V128.22.578.578","article-title":"The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in aml - a randomized trial in patient-derived xenografts","volume":"128","author":"Bruedigam","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2023082115442273800_bib110","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.V130.Suppl_1.798.798","article-title":"Integrated molecular analysis identifies replicative stress as sensitizer to imetelstat therapy in AML","volume":"130","author":"Bruedigam","year":"2017","journal-title":"Blood"},{"key":"2023082115442273800_bib111","first-page":"2023.04.25.538357","article-title":"Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as therapeutic strategy for acute myeloid leukemia","author":"Bruedigam","year":"2023","journal-title":"bioRxiv"},{"issue":"suppl 1","key":"2023082115442273800_bib112","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2022-168166","article-title":"Imetelstat-mediated alterations in lipid metabolism to induce ferroptosis as therapeutic strategy for acute myeloid leukemia","volume":"140","author":"Bruedigam","year":"2022","journal-title":"Blood"},{"issue":"suppl_13","key":"2023082115442273800_bib113","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1158\/1538-7445.AM2017-1101","article-title":"Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivoin acute myeloid leukemia [abstract]","volume":"77","author":"Rusbuldt","year":"2017","journal-title":"American Association for Cancer Research"},{"issue":"suppl_14","key":"2023082115442273800_bib114","first-page":"2731","article-title":"Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines [abstract]","volume":"76","author":"Rusbuldt","year":"2017","journal-title":"American Association for Cancer Research"},{"issue":"7","key":"2023082115442273800_bib115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4302\/2072657\/blooda_adv-2023-009903-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4302\/2072657\/blooda_adv-2023-009903-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T15:45:48Z","timestamp":1692632748000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/16\/4302\/495950\/Telomerase-targeted-therapies-in-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":115,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009903","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]}}}